Amgen Wins Order Blocking Colorado's Enbrel Price Cap
Colorado is preliminarily blocked from enforcing its price cap on Amgen's rheumatoid arthritis drug Enbrel, a federal judge ruled Wednesday, saying the biotech company is likely to succeed on its claim...To view the full article, register now.
Already a subscriber? Click here to view full article